title: Uveal melanoma therapy on the horizon?
abstract: A phase II trial of the MEK inhibitor selumetinib offers hope for patients with metastatic uveal melanoma, a rare and fatal eye cancer.
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D014604:Uveal Neoplasms / Q000188:drug therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D001562:Benzimidazoles; D003606:Dacarbazine